Agomab Spain S.L.

4 trials Commercial sponsor Merged from 2 name variants

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

0 Recruiting

4 Completed trials

7 Countries active

2 Unique IMPs

100% Results reported

Phase II

Phase I (Other)

Phase II: 1 Phase I (Other): 3

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Crohn's disease 1

Top IMPs

ORG-129 2 MIDAZOLAM 1

All trials

4 total

A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease. Ended

2022-502789-26-01 Phase II 6 countries ORG-129
A study to Learn How Safe AGMB-129 is in Healthy Adults Taking Multiple Doses of AGMB-129 That Are Increased a Little at a Time Ended

2025-521705-40-00 Phase I (Other) 1 country
Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants Ended

2023-504460-41-00 Phase I (Other) 1 country
Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants Ended

2023-504461-23-00 Phase I (Other) 1 country MIDAZOLAM; ORG-129

Showing 1–4 of 4 trials

← All sponsors A–Z